BOSTON SCIENTIFIC CORP — Director's Dealing 2021

Jul 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2021-07-27

Reporting Person: Scanlon Meghan (SVP,Pres,Urology Pelvic Health)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-27	Common Stock	M	13850.0000	$23.4100	Acquired	32992.0000	Direct
2021-07-27	Common Stock	S	13850.0000	$45.0100	Disposed	19142.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-27	Stock Option (Right to Buy)	$23.4100	M	13850.0000	Disposed	2026-07-01	Common Stock (13850.0000)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

F3: Represents the weighted average sale price. These shares were sold in multiple transactions at $45.00 and $45.02. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: Grant to the reporting person of an option to purchase 13,850 shares of common stock vesting in four equal annual installments beginning on July 1, 2017, the first anniversaryof the date of grant.